2000•BoneRequires access

Phosphodiesterase inhibitors, pentoxifylline and rolipram, increase bone mass mainly by promoting bone formation in normal mice

T. Kinoshita, Shinji Kobayashi, Sohei Ebara, Yasuo Yoshimura, Hiroshi Horiuchi, Takahiro Tsutsumimoto, S. Wakabayashi, Kunio Takaoka

Open publisher page 101 citations

Abstract

This record does not include an abstract. Use the full-text link above if available.

About this research paper

What this paper is about

An abstract is not available in the OpenAlex record for this paper.

Why it matters

OpenAlex reports 101 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Key concepts: Rolipram, Pentoxifylline, Phosphodiesterase inhibitor, Endocrinology, Internal medicine, Cancellous bone, Phosphodiesterase, Osteoporosis

Back to paper search Browse research topics Original source

Phosphodiesterase inhibitors, pentoxifylline and rolipram, increase bone mass mainly by promoting bone formation in normal mice — Research Paper | ScholarLens